LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Allogene Therapeutics Inc

Открыт

СекторЗдравоохранение

1.18 -0.84

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

1.15

Макс.

1.19

Ключевые показатели

By Trading Economics

Доход

8.8M

-51M

Рентабельность продаж

272,450

Сотрудники

226

EBITDA

-335K

-57M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+541.38% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

6 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

39M

264M

Предыдущая цена открытия

2.02

Предыдущая цена закрытия

1.18

Новостные настроения

By Acuity

25%

75%

44 / 372 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Allogene Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

27 авг. 2025 г., 22:51 UTC

Отчет

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 авг. 2025 г., 23:57 UTC

Отчет

Trip.com Group 1H Rev $4.01B

27 авг. 2025 г., 23:57 UTC

Отчет

Trip.com Group 1H Adj EPS $1.84

27 авг. 2025 г., 23:57 UTC

Отчет

Trip.com Group 1H EPS $1.82

27 авг. 2025 г., 23:50 UTC

Обсуждения рынка

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 авг. 2025 г., 23:39 UTC

Отчет

Correction to Nvidia Earnings Article -- WSJ

27 авг. 2025 г., 22:59 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

27 авг. 2025 г., 22:59 UTC

Обсуждения рынка

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 авг. 2025 г., 22:58 UTC

Отчет

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 авг. 2025 г., 22:57 UTC

Отчет

South32 FY Free Cash Flow $192 Million

27 авг. 2025 г., 22:56 UTC

Отчет

South32 FY Total Capital Expenditure $1.35 Billion

27 авг. 2025 г., 22:56 UTC

Отчет

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 авг. 2025 г., 22:55 UTC

Отчет

South32 Net Cash $123 Million at June 30

27 авг. 2025 г., 22:54 UTC

Отчет

South32: Focused on Maintaining Strong Operating Momentum

27 авг. 2025 г., 22:53 UTC

Отчет

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 авг. 2025 г., 22:53 UTC

Отчет

South32 Extends Capital Management Program for 12 Months

27 авг. 2025 г., 22:52 UTC

Отчет

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 авг. 2025 г., 22:51 UTC

Отчет

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 авг. 2025 г., 22:51 UTC

Отчет

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 авг. 2025 г., 22:50 UTC

Отчет

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 авг. 2025 г., 22:50 UTC

Отчет

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 авг. 2025 г., 22:45 UTC

Отчет

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 авг. 2025 г., 22:44 UTC

Отчет

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 авг. 2025 г., 22:44 UTC

Отчет

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 авг. 2025 г., 22:43 UTC

Отчет

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 авг. 2025 г., 22:43 UTC

Отчет

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 авг. 2025 г., 22:42 UTC

Отчет

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 авг. 2025 г., 22:42 UTC

Отчет

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 авг. 2025 г., 22:40 UTC

Отчет

Sandfire Resources Net Debt $123 Million at June 30

27 авг. 2025 г., 22:40 UTC

Отчет

Sandfire Resources FY Underlying Ebitda $527.7 Million

Сравнение c конкурентами

Изменение цены

Allogene Therapeutics Inc Прогноз

Целевая цена

By TipRanks

541.38% рост

Прогноз на 12 месяцев

Средняя 7.44 USD  541.38%

Максимум 14 USD

Минимум 1 USD

Основано на мнении 14 аналитиков Wall Street, спрогнозировавших целевые цены для Allogene Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

14 ratings

10

Покупка

4

Удержание

0

Продажа

Техническая оценка

By Trading Central

1.18 / 1.69Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Weak Bullish Evidence

Долгосрочная

Weak Bearish Evidence

Настроения

By Acuity

44 / 372Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.